Effects of empagliflozin on cardiac and vascular hemodynamic markers by subgroups of age, sex and hypertension in patients with T2DM and high CV risk: EMPA-reg outcome.
Event:
ESC Congress 2017
Topic:
Drug therapy
Session:
Optimising cardiovascular pharmacotherapy